|Articles|July 13, 2020
COVID-19 Disruption of Trials is in Decline
Advertisement
Most disruptions to clinical trials over the past three months were caused by the suspension of enrollment, followed by slow enrollment, and delayed initiation, says GlobalData, a data and analytics company. The number of disrupted trials began to fall between June and July.
For more information, click
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Breaking the Efficacy Ceiling in IBD and Beyond
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
5